This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Expert Panel Discussion: Complicated Treatment Decisions in NSCLC

Expert Panel Discussion: Complicated Treatment Decisions in NSCLC

Format

Interactive Monograph

Time to Complete

1 hour

Released

December 27, 2017

Expires

December 27, 2018
Add to Queue


Maximum Credits

1.00 AMA PRA Category 1 CreditTM

Accredited Provider

Joint providership of American Academy of CME, Inc., (Academy) and CME Matters LLC

Commercial Supporter

Supported by Genentech

Program Description

Each year, it has become more complicated to factor in new data to optimize therapeutic management for patients with lung cancer. However, it continues to become more interesting as we optimize therapy for individual patients, with the goal of maximizing benefit and minimizing toxicity. Consequently, oncologists must work closely with pathologists to ensure appropriate testing has been done prior to initiating therapy.

We have gathered a panel of experts to discuss some of the more complicated treatment decisions in representative lung cancer clinical scenarios, highlighting both the agreement and differences in treatment decisions between the panel members.

Intended Audience

This activity has been designed to meet the educational needs of oncologists.

Educational Objectives

After completing this activity, the participant will be better able to:

  • Assess the most current safety and efficacy data and guideline recommendations associated with evidence-based targeted therapies
  • Select the most appropriate patients for anti-VEGF therapy based on individualized characteristics, comorbidities, risk factors, and current clinical evidence
  • Identify the role of novel immunotherapies in the use of individualized targeted therapies for advanced NSCLC
  • Incorporate updated genomic testing guidelines and streamlined algorithms for evidence-based targeted treatments of NSCLC patients

Conflict Of Interest Disclosure Policy

All faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Faculty

Joel Neal, MD, PhD
Assistant Professor of Medicine - Oncology
Stanford University Medical Center

Dr. Neal has affiliations with CARET Physicians Resource Management, Clovis Oncology, Nektar Therapeutics, and Boehringer Ingelheim (Consultant – marketing); Argule, Boehringer Ingelheim, Exelixis, Genentech/Roche, Merck, Nektar Therapeutics, and Novartis (Grant Recipient).

Lecia V. Sequist, MD, MPH
Associate Professor, Department of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center

Dr. Sequist has affiliations with AstraZeneca, Pfizer, Novartis, Merrimack, Boehringer Ingelheim, Genentech (Advisory Board/Scientific Consultant); Novartis, Boehringer Ingelheim, Merrimack, and Genentech (Grant Recipient - all to institution)

Nathan A. Pennell, MD, PhD
Associate Professor and Director
Lung Cancer Medical Oncology Program
Cleveland Clinic Taussig Cancer Institute

Dr. Pennell has affiliations with AstraZeneca, Eli Lilly, and Regeneron (Advisory Board)

Accredited Provider Disclosure

Cathy Pagano, CHCP, and Anita Misra-Press (CME Matters LLC) and John JD Juchniewicz, MCIS, CHCP (American Academy of CME, Inc.), have disclosed that they have no relevant financial relationships specific to the subject matter within the past 12 months.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Academy of CME, Inc., (Academy) and CME Matters LLC. The Academy is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Academy designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This activity will review off-label or investigational information.

Disclaimer

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CME Matters. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

THIS ACTIVITY WAS DEVELOPED IN SEPTEMBER 2017; DATA IS ACCURATE AS OF THAT DATE.

For any questions, please contact: CEServices@academycme.org or cpagano@cmematters.org.

Instructions

There is no fee to participate in this activity. Participants must review all activity information, including the
learning objectives, disclosure statements, and content. A statement of credit will be available to print from your CME History on myCME. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Successfully complete the post-test, activity evaluation, and claim credit. A post-test score of 75% or higher is required, and you may retake the post-test up to 2 times to achieve a passing score.
  • Your certificate will be available to print from your CME History, located under My Account.
Add to Queue